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Along with the development of new technology, the
molecular mechanisms of the generation of functional CTLs
have been elucidated over the last several years which
together will undoubtedly enhance our progression towards
the development of successful vaccines for the many chronic
viral infections and cancer. It has been shown that the
activation of na¨ ıve CTLs requires all three signals to be fully
activated: antigen, costimulation, and third signal, which
can be provided by inﬂammatory cytokines such as IL-12
and type I IFNs. In addition, diﬀerentiation of memory
CTLs requires survival signals and γc-cytokines such as IL-
2, IL-7, and IL-15. With the booming information on CTLs
activation and their application, we felt it was in urgent need
to launcha specialissue focusing on the most recentprogress
on CTL research.
We expected an active response to our call for this special
issue and indeed are satisﬁed with the large number of
submissions and quick and accurate response of authors
to all the reviews and editorial comments. The selected
research manuscripts cover a broad area of CTL research,
including studies to deﬁne new strategies for vaccination
against devastating chronic infections like HIV, tumor
therapies deﬁning novel tumor-speciﬁc epitopes for CTLs,
andstrategiestoenhancecancercontrol.Interestingattempts
have been made to indentify nontraditional adjuvants such
as bacteriophages and β-glucan oligosaccharides while other
groups have used unique vectors and cytokines for vaccina-
tion studies. Interestingly, this issue attracted a large number
of review articles which address the mechanisms of CTL
activation, new function of CTLs, vaccine development for
viral infections, new adjuvant exploration, and the most up-
to-date progress in cancer vaccine and cancer therapy.
We thank all of the authors for their enthusiasm in
submitting their manuscripts to this special issue and appre-
ciate their eﬀorts and time in process of their manuscripts.
Acknowledgement should certainly go to all of the reviewers,
most of whom reviewed at least two versions of the
same manuscript. Their sacriﬁce of research time is highly
appreciated. We hope the original scientiﬁc discoveries and
summarized information within this special issue will be
helpful and promote new avenues of exploration for scien-
tists studying CTLs in the context of vaccine development.
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